Sapiens · Weight

Weight Loss Treatment in India: Medicines, Costs and Who It’s For

Medical weight loss means treating excess weight as the medical condition it is: a clinical assessment on Indian criteria, tests chosen to answer useful questions, prescription medicines where they are indicated, a diet and strength plan that protects muscle, and monitoring that adjusts treatment to your response. The medicine, where one is used, sits inside that process.

The reason this page exists now is simple. For the first time, weight loss treatment in India includes medicines that can produce loss approaching the lower end of what was once achievable mainly through surgery, at prices that fell by up to half in a year. What has not changed is that a prescription alone is not obesity care. Eligibility, dosing, nutrition, training, side-effect management and a long-term plan materially change what happens around the medicine, and this guide covers all of it: who treatment is for, what every option delivers, what things cost, and how the process actually runs. Each deep topic has its own guide on this site; this is where they connect.

What excess weight actually does Copy link

Start with why this is medicine’s business at all. Excess adiposity, particularly the abdominal kind Indians carry early, contributes to or worsens many of India’s biggest chronic diseases: type 2 diabetes, hypertension, heart disease, fatty liver, obstructive sleep apnoea, PCOS and infertility, osteoarthritis of the knees and spine, and a documented toll on mood and self-esteem.¹ Indians develop these complications at lower body weights than Western populations, which is why India rewrote its obesity definition in 2025 and formally treats obesity as a chronic disease, staged and managed like one.¹

Now the hopeful half, which is, of course, the half people are rarely told. This trajectory bends. Even 5–10% weight loss can produce clinically meaningful improvements in blood sugar, blood pressure, triglycerides and liver fat, and several conditions keep improving with larger losses. Sleep returns before the target weight does. Knees complain less within months. In prediabetes, sustained weight loss can substantially cut the risk of progressing to type 2 diabetes, and some people return to normal blood sugar altogether. Treating weight is not a cosmetic project with health benefits attached; it is disease modification, and for many people it is the single intervention that improves five problems at once.

The opinions you will hear Copy link

Decide to treat your weight medically in India and, naturally, the commentary arrives before the prescription does. Just eat less. Walk after dinner. Our whole family is built like this. Injections are cheating. And, in a lower voice, the worried ones: is that not what bodybuilders take? What about side effects? Is there even long-term data? If you have ever sat through a family lunch where your plate was the main topic, you know the tone. Most of it comes from people who love you, all of it lands, and each worry deserves a calm answer, starting with the oldest: that weight is a test of character.

It is not a test of character; it is regulated biology. Appetite, satiety and the body’s defence of its own weight are run by hormonal circuits with a genetic loading, and those circuits push back against dieting with an efficiency that has nothing to do with discipline. This is precisely why medicine now treats obesity as a chronic disease and why the newest treatments work on those circuits directly. Nobody calls a blood pressure tablet cheating. Nobody suggests treating a thyroid condition with more willpower. Weight is the last condition where trying medicine is read as a personal failure, and that reading keeps people who qualify for treatment away from it for years while the complications compound quietly.

Take the steroid comparison next, because it is usually the first image that arrives: a syringe, a gym bag, a shortcut with a price. The picture borrows everything from the needle and nothing from the drug. What bodybuilders misuse are anabolic-androgenic steroids, muscle-building hormones that do have legitimate medical uses; the gym pattern takes them at many multiples of what a body produces, without indication or oversight, for performance, and that pattern of use is what carries the famous harms and what anti-doping rules ban. Weight-loss medicines are different objects altogether. Semaglutide copies a satiety hormone your own gut releases after every meal, tirzepatide works through two such gut-hormone receptors at once, and both are prescribed for a diagnosed disease at licensed doses, titrated, monitored and reversible. The two share a route of administration and nothing else; mechanism, purpose, dose logic and evidence all separate them, and judging a medicine by its needle is like judging a book by its courier.

The side effects are real, and the fear of them deserves a straight answer. The common ones are gastrointestinal: nausea, constipation, reflux, sometimes vomiting, concentrated in the early dose-escalation weeks and settling as the body adapts, which is exactly why doses climb slowly and why supervision exists. Serious harms are rare, screened for before prescribing, and covered without varnish later in this guide. Weigh them against the side effects of the untreated disease, because obesity has those too: type 2 diabetes, heart attack, fatty liver, apnoeic nights, knees that age ahead of their owner. The cleanest data on that trade comes from SELECT, the largest completed trial of this class in people without diabetes. Across more than three years, 17,604 adults with established heart disease took weekly semaglutide or placebo; the treated group had a 20% lower risk of major cardiovascular events and fewer serious adverse events overall, although more people on semaglutide stopped treatment because of side effects.¹⁹ Fewer of them died, too: deaths from any cause ran 19% lower in the treated group, a result the trial reports as supportive, short of formal proof, and one that is hard to square with the idea of a reckless drug.¹⁹ The conversation has even reached ageing research, where scientists are now studying and openly debating whether this class of medicines could extend healthy lifespan.²¹ That question is young, unsettled, and no reason on its own to take one, but it is a strange reputation for a medicine the drawing room compares to a gym syringe.

On long-term safety, the record is longer than the panic suggests. The first medicine of this class was licensed for type 2 diabetes in 2005, which means two full decades of continuous prescribing and pharmacovigilance sit behind the current generation.²⁰ That watchfulness is the point: it is how a very rare eye condition was identified for semaglutide and written into its labels in 2025, and it is how rarer signals will keep surfacing if they exist, with labels changing as the accumulated evidence directs.¹⁶ The genuinely newer territory is multi-year use for weight in people without diabetes, and the honest answer there is that four years of SELECT follow-up show the weight loss holding and fewer serious adverse events on treatment.¹⁹ Unknowns remain past that horizon, as they do for every medicine, and they belong in the consult, where your own risks are weighed against your own disease.

All of which returns the commentary to its proper size. The relatives and colleagues offering it mean well, and they will carry none of it: the sugar readings are yours, the breathless staircase is yours, and so is every good year a treated disease gives back. You do not owe anyone a defence of a medical decision made with a doctor; the drawing-room jury does not get a vote. Privacy remains a legitimate design requirement too, and good care should be reachable without announcing itself, a point this guide returns to when it walks through the process. So listen politely, change the subject, and let the follow-up bloods do the arguing.

The stages of obesity in India, and the treatment at each Copy link

India rewrote its obesity rulebook across 2025 and 2026, and the revision decides whether you get treated, and with what. Indians develop diabetes, fatty liver and heart disease at lower body weights than Western populations, so the Indian scale starts earlier: obesity itself begins once your BMI crosses 23.¹ From there, one word needs care, because two different rulers both use it: stage. The first ruler is the diagnosis, from the 2025 Indian definition: it grades your BMI from I to IV and splits obesity into Stage 1 and Stage 2 by what the weight is doing to you.¹ The second is the severity ladder your doctor plans treatment on: five stages, 0 to 4, adopted for India in 2026 when the endocrinologists’ and obesity surgeons’ societies agreed on a single national obesity treatment algorithm.²³ The plate reads the ladder top to bottom; the sections after it walk both rulers in order, and this guide names which ruler it means every time.

The normal band: nothing to treat, one thing to watch

If your BMI sits below 23 and your waist inside 90 cm (men) or 80 cm (women), you will usually sit outside the framework’s criteria: nothing to treat, no treatment indicated. The exception is written into the framework itself, because BMI is a screen and can miss adiposity in Indian bodies: a high body-fat percentage can establish obesity even at your lower BMI.¹ So give the tape measure a yearly look, because it is your waist, along with what follows it, that moves you up this ladder.

Stage 1 of the diagnosis: weight without consequences yet

Stage 1 is the beginning: your BMI is above 23, but your blood sugar, blood pressure and lipids are normal, nothing limits your day, and no obesity-linked disease has arrived.¹ The fat has accumulated; the consequences have not. Your treatment here is lifestyle, prescribed with the same seriousness as a medicine: eat roughly 500 kcal a day less than you burn, build up to about an hour of movement daily, and lift weights at least three days a week to protect your muscle.¹ Behavioural support makes it stick, and the aim is losing half a kilogram to a kilogram a week.¹ For most people at this stage, that is the whole prescription. Medicine becomes an option in three situations only: your BMI reaches 27.5, you gain more than 10% despite genuinely doing the lifestyle work, or your risk of tipping into Stage 2 is high, say a family loaded with early diabetes.¹

Stage 2 of the diagnosis: adiposity with effects

Stage 2 is the same disease with consequences attached, and it takes three things together: the BMI, the waist (90 cm in men, 80 cm in women, or a waist-to-height ratio above 0.5), and something the weight is already doing to you.¹ That something can be a limit on daily life, breathlessness on the stairs, knees complaining on ordinary tasks, or an established linked condition: prediabetes, type 2 diabetes, fatty liver, dyslipidaemia, hypertension, sleep apnoea, PCOS.¹ If that describes you, treatment changes gear: your lifestyle work continues at full intensity, and medication enters early, as standard, chosen to your profile and grade.¹ Coupled with lifestyle, expect roughly half a kilogram a week and 5–10% below your baseline within three to six months, carried by adequate protein, resistance training and scheduled monitoring.¹¹³ Most of the rest of this guide is about doing this stage well.

The severity ladder: stages 0 to 4

The diagnosis says whether obesity exists. The ladder says how serious it has become, and that is the number your treatment is actually planned on. In 2026, eighty specialists from the Endocrine Society of India and the Obesity Surgeons Society of India voted, unanimously, to run India’s treatment decisions on a stage-wise algorithm built on the Edmonton Obesity Staging System, adapted to the Indian definition and Indian resources.²³ Where the diagnosis asks about your measurements, the ladder asks a harder question: what has the weight already done?

Climb it with your own reports in hand.²⁴ Stage 0 means no signs yet: your sugar, pressure and lipids are normal, nothing hurts, nothing limits you; the treatment is lifestyle, to keep you here. Stage 1 means early warnings: borderline blood pressure, sugar or liver enzymes, mild aches, mild limits; lifestyle at full intensity, watched closely. Stage 2 means an established disease has arrived, diabetes, hypertension, sleep apnoea, PCOS or joint disease, and this is the rung where weight-loss medicine typically joins the plan; the ladder’s own management logic says so, and the endocrine society’s prescription thresholds, next section, point to the same place.²⁴²² Stage 3 means organ damage: a heart attack, heart failure, diabetic complications, joint disease that disables; treatment turns intensive and surgery is actively considered. Stage 4 is severe, end-stage disability from obesity-linked disease, managed aggressively, as feasible, at specialist centres. In cohort studies, this stage number predicts mortality better than BMI does, which is exactly why your doctor cares more about your reports than your weight.²⁴

The rulers agree with each other. The diagnosis’s Stage 1 sits on the ladder’s lowest rungs; its Stage 2, defined by disease or daily-life limits, lands you on rung 2 or higher, where the medicine conversation begins on both systems.

So when do doctors actually start the medicine?

India now has a second yardstick beside the staging, from the Endocrine Society of India’s 2025 practice guidelines, and it answers the question in numbers you can check against your own. Their threshold: a BMI above 27 on its own, or above 25 with one linked condition such as hypertension, dyslipidaemia, type 2 diabetes or sleep apnoea.²² Read together, the message of both systems is the same: what starts the medicine is your risk, carried by your waist and your comorbidities, and only partly your BMI. The endocrinologists add a discipline the staging leaves implicit: the medicine has to earn its place, with about 5% of body weight off by month three counting as a working response, and a change of plan if it is not.²² They even match molecule to ambition, favouring tirzepatide where 15–20% loss is the target and either weekly molecule for 10–15%.²²

The surgical rungs

Surgery sits above the stages, on thresholds of its own. OSSI considers it from a BMI of 32.5 with an obesity-linked condition, 37.5 without one, and 30 where the disease is life-threatening.¹⁵ The 2025 framework separately supports it from 35 in any case, and from 27.5 in uncontrolled type 2 diabetes.¹ The dedicated section below covers what the operations involve. The whole ladder, drawn to one line:

Who qualifies for weight-loss medication in India? Copy link

With the scale in hand, the qualification question has a short answer: medication enters as standard at Stage 2, and remains admissible in the three selected Stage 1 situations above. In practice the assessment takes minutes: height, weight, a tape measure and your history, and it is worth taking the grades and stages with you to your consult, because they are the map your doctor will use.

One distinction is worth pinning down, because it trips people up. The framework is a clinical staging system; it does not replace the approved indication of any particular medicine, and each product carries its own regulatory label. Weight-management semaglutide, for instance, is labelled for an initial BMI of at least 30, or at least 27 with a weight-related condition, thresholds the Wegovy guide covers in detail. A prescriber therefore applies both: the framework to decide whether treating is right, and the label to decide whether a given product fits. Cosmetic use sits nowhere on this ladder. These are potent treatments for people whose weight is harming their health, judged on Indian thresholds, and a doctor may reasonably decline to prescribe even inside the brackets. The assessment also looks for contributors worth treating in their own right, such as an underactive thyroid, certain medications, or untreated sleep apnoea; the thyroid–weight connection has its own guide.

The toolkit: what each treatment delivers Copy link

Every option in weight medicine now has a landmark trial, which makes a fair comparison possible as long as one rule travels with it: these are different trials in different people, so read the numbers as a sense of scale, never as a race.

Read from the bottom of the ladder up; as you would expect, the newest molecules sit nearest the top. Look AHEAD shows what a highly structured lifestyle programme can achieve in a trial: 8.6% average loss in year one with intensive coaching, an average that drifted down in later years.² It is also the floor under everything else, because every drug trial ran on top of diet and activity support. Orlistat, long the only medicine actually licensed for obesity in India, adds roughly 3% beyond placebo.³ Daily liraglutide, the first GLP-1 built for weight, averaged 8.0% over 56 weeks, though the 3 mg weight-loss dose has not been marketed in India, as the 2025 Indian consensus records.⁴ Weekly semaglutide moved the field: 14.9% over 68 weeks, with 86% of participants losing at least 5%.⁵ Tirzepatide, a dual-hormone molecule working through both GIP and GLP-1, averaged 20.9% at its top dose over 72 weeks.⁶ The one direct comparison, SURMOUNT-5, put the gap at 6.5 percentage points: 20.2% for tirzepatide, 13.7% for semaglutide.⁷ Bariatric surgery still holds the crown for size and durability, typically 25–30% in the first two years.⁸

A pair of footnotes belongs under that chart. Real-world losses usually run below trial averages, because trials add structure most pharmacies do not. And the goal is health, with the scale as its proxy: the metabolic gains arrive well before any trial average is reached.

Do weight loss tablets actually work? Copy link

“Weight loss tablets” and “weight loss pills” are what India actually searches for, and the phrases cover three different shelves, so the side effects and the results depend entirely on which shelf you are holding.

The short answer is yes, two kinds, each with a caveat. Oral semaglutide exists in India as Rybelsus and, since May 2026, as Dr Reddy’s Obeda, launched in 3, 7 and 14 mg strengths at ₹99, ₹135 and ₹225 a tablet, roughly ₹3,000–6,800 a month depending on strength.⁹ One precision matters: oral semaglutide is licensed in India for type 2 diabetes, so using these tablets specifically for weight depends on the product’s approved indication and may be off-label, a judgement that belongs to your prescriber.¹ The tablet is also absorbed far less efficiently than the injection and is taken fasting with strict timing. The generic semaglutide guide covers the oral brands and prices.

Orlistat is the other real tablet, and it deserves a proper introduction rather than a dismissal, because for years it was the only drug formally licensed for obesity in India and it remains on the framework’s list.¹ It works in the gut, where it blocks pancreatic lipases, so about a third of the fat you eat passes through unabsorbed. Averaged across one-year trials it delivers roughly 3% of body weight beyond placebo, and it modestly improves blood pressure, lipids and the risk of progressing to diabetes.³ Its costs are equally concrete: oily stools, urgency and wind, especially after fatty meals, which is why adherence is its weak point, and it can lower fat-soluble vitamin absorption. It is not used in pregnancy and is contraindicated in chronic malabsorption and cholestasis. Kidney disease or a history of oxalate stones calls for extra caution, because orlistat can raise oxalate-related renal risk.¹ Where it still fits: people who cannot take or afford a GLP-1, as an add-on in selected cases, and for anyone whose main enemy is a high-fat diet. It is honest, cheap and unglamorous, and it is medicine.

The second shelf is the pharmacy’s front rack and Instagram’s entire economy: fat burners, garcinia, apple-cider-vinegar gummies, “slimming” teas and capsules. These sit under food and supplement rules, a far lighter regime than prescription medicines, and the problem is the mismatch: the clinical evidence behind them does not approach the claims on the labels, and some have been linked to liver injury. The third shelf is the grey market of unlabelled peptides and copied pens, covered under the law section below. A working rule collapses all three shelves: the medicines with strong weight-loss evidence in India are prescription products. So treat any over-the-counter tablet promising large, effortless loss with scepticism, and if a tablet genuinely interests you, ask your prescriber where it fits before you spend on it.

The medicines and their prices Copy link

Indian weight medicine now runs on a pair of molecules, both weekly weight loss injections, sold under several brands. For the drug class itself, how these medicines work, dosing, safety and what happens when you stop, see the GLP-1 medications guide. Prices below are from current pharmacy listings, manufacturer information or wire reporting, checked August 2026; this market has repriced repeatedly, and online pharmacies routinely discount below MRP, so treat the figures as listed ceilings and check the printed MRP before you pay.¹⁰

The market context explains the prices. Semaglutide’s patent expired on 20 March 2026 and more than a dozen Indian companies launched generics, forcing branded prices down by up to 48%.¹⁰ Tirzepatide has no generic, which is why its pens hold their listed range and why it now dominates: India’s GLP-1 market tripled in a year to ₹1,736 crore, with tirzepatide at 63% of the value.¹¹ Choosing between the molecules weighs efficacy, heart-outcome evidence, price and availability; the head-to-head comparison lays it out. Liraglutide remains on Indian shelves at diabetes doses and now trails the weekly molecules on every axis except track-record length.

Do you lose muscle on weight-loss medication? Copy link

Some, yes, and this is the least-discussed number in Indian weight medicine. In the STEP 1 body-composition sub-study, total fat fell 19.3% and visceral fat 27.4%, while lean body mass fell 9.7%; across GLP-1 sub-studies, lean tissue has made up roughly a quarter to two-fifths of the total weight lost.¹² A couple of precisions keep that honest. Lean mass is not the same thing as muscle, since it also counts water and organ tissue, and some lean loss accompanies any large weight loss by any method. Fat fell much faster, so body composition still improved. The concern is real anyway: losing strength while losing weight is a bad trade, especially in a population already prone to low muscle mass.

The countermeasures now carry a four-society clinical advisory, no longer just gym folklore: adequate protein, around 1.2–1.6 g per kilo per day for many appropriate adults and individualised for kidney function, age and body size, plus resistance training to preserve muscle and bone.¹³ This is where the Indian context bites hardest. Hitting a protein target on a largely vegetarian, carbohydrate-forward plate with a medically suppressed appetite is genuinely difficult, and festival and wedding seasons are real. In practice that means a protein target with the mathematics done for you, built out of dal, paneer, curd, soya and eggs, and a twice-weekly strength habit boring enough to survive a busy week. Both are as much a part of the treatment as the pen.

What supervision changes Copy link

Supervision reduces the avoidable problems: inappropriate prescribing, unmanaged side effects, inadequate nutrition, preventable lean-tissue loss, and treatment abandoned without a long-term plan.¹³ Three moments decide most outcomes.

The early weeks come first. Gut side effects are front-loaded and cluster around dose increases; unmanaged, they are why people quit or end up dehydrated. Managed, with smaller meals, hydration, and a dose climb that pauses when your gut says pause, most people get through. Tell your doctor early; early is when side effects are easiest to fix. The full pattern, including the rarer risks, is in the side-effects guide.

The plateau comes second. Weight loss on these medicines slows and stalls after months, which is expected physiology. The difference between a plateau read as failure and a plateau read as a checkpoint is usually whether anyone qualified is watching, reviewing the dose, the protein, the training and the sleep before anything is abandoned.

Stopping comes third, and deserves its own honesty. These medicines quiet a chronic biological drive; they do not delete it. In the semaglutide trial extension, participants regained about two-thirds of their lost weight in the year after the last injection, with the metabolic gains fading alongside.¹⁴ Chronic conditions do this when their treatment is withdrawn. What the evidence supports is planning, and the plan is individual: continued treatment where appropriate, nutrition and activity support carrying more of the load, and monitoring for regain, all designed with your doctor before the first dose is ever taken.

The process, end to end Copy link

Here is what good medical weight loss actually looks like from the inside. Much of it, as you will see, can be delivered remotely when that is clinically appropriate, which changes who actually gets treated.

It opens with an assessment, because eligibility is a clinical judgement: your measurements against the Indian staging, your history, your medications, the conditions that would change or exclude treatment. Testing follows only where it answers a question, and then a doctor consult sets the plan: whether medicine is indicated at all, which one, at what starting dose, with what watch-list. A dietitian then builds the food plan around your actual plate, vegetarian or not, with the protein mathematics done for you, and the strength work scaled to where you are starting from.

Then comes the part traditional care does worst: the weeks between consultations, which is where treatment is actually lived. This is the gap a well-designed programme closes: a companion beside you, in the app, day to day. It tracks your weight trend, food and protein, side effects and mood. It answers questions and gives non-medical guidance at eleven at night, when the nausea question actually occurs to you. It watches for red flags and escalates them to your doctor, so they never wait for the next appointment. And it quietly assembles all of it into a report, so your next consultation starts from what actually happened, in place of whatever you can remember of it. You can message your doctor when something needs a doctor. Medical decisions stay with the clinician; the companion’s job is to make those decisions better informed and better timed.

Follow-up consults then adjust what already exists: dose moved or held, protein rebuilt, a plateau examined, repeat tests when they will change something. In time the conversation turns to maintenance, which was part of the design from day one. And when your situation allows it, the whole rhythm runs from home, on your schedule, visible to nobody but you and your clinical team, with in-person care folded in whenever your doctor judges it necessary. For a condition this wrapped in other people’s opinions, that privacy is not a convenience feature; it is often the difference between starting and not starting.

The blood tests: chosen, never bundled Copy link

The first step is a clinical assessment, and testing is then selected to answer useful questions rather than run as a ritual. HbA1c places you on the diabetes spectrum, where many people learn they are further along than they thought. A lipid profile maps the cardiovascular risk that excess weight compounds. Liver enzymes matter where fatty liver is suspected, kidney function where history or a proposed medicine makes it relevant, and thyroid testing when symptoms or history point that way. A structured panel can be a sensible vehicle when several of those questions apply at once; the questions come first, the panel second.

What the results do is the point. They screen for what contributes to weight gain and for the complications already travelling with it, and finding diabetes, fatty liver, dyslipidaemia, thyroid disease or sleep apnoea can materially change the plan. Bring any old reports you have to the first consult; trends beat snapshots. Repeat testing during treatment then shows the response beyond the scale: falling HbA1c, improving enzymes, lipids moving the right way. That is what treating metabolism, with weight as its most visible marker, looks like on paper.

Bariatric surgery: the top of the ladder Copy link

Nobody starts this conversation at surgery, and of course very few people end there either. Yet it remains the most powerful tool in weight medicine, and Indian thresholds sit lower than Western ones for the same reason the BMI scale starts earlier here. Two Indian sources set the criteria, and they deserve separate attribution. OSSI’s current guidance considers surgery from a BMI of 32.5 with an obesity-related condition, from 37.5 without one, and from 30 where obesity-linked disease is life-threatening, with uncontrolled diabetes, cardiomyopathy and severe sleep apnoea the named examples.¹⁵ The 2025 Indian framework, separately, recommends surgery from a BMI of 35 regardless of comorbidity, from 30 with comorbidities unresponsive to optimal lifestyle and drug treatment, and metabolic surgery from 27.5 in uncontrolled type 2 diabetes.¹

The two main types performed in India are sleeve gastrectomy, which removes most of the stomach, and gastric bypass, which reroutes it; banding has largely fallen away. What surgery delivers is a different order of result: typically 25–30% of body weight in the first two years, substantial loss still held a decade later, and remission of type 2 diabetes in a large share of patients.⁸ What it asks is also different. It is major surgery, it commits you to lifelong supplementation and follow-up, and candidacy runs through a multidisciplinary assessment, usually after supervised non-surgical treatment has been given a real chance. Costs in India typically run to a few lakh rupees, varying by procedure, hospital and city. The GLP-1 era has not retired surgery; it has clarified its place at the top of a ladder more people can now climb without reaching it.

Who should not take these medicines Copy link

This is the cluster’s reference list for the GLP-1 class, and the spoke guides link back here. It splits into a hard tier and a judgement tier, for different reasons.

The hard stops. A personal or family history of medullary thyroid carcinoma or MEN 2 syndrome: these molecules caused thyroid C-cell tumours in rodents, and whether that translates to humans remains unknown, so the family history closes the door. A previous serious allergic reaction to the molecule. And pregnancy: these medicines are never used for weight loss in pregnancy, and the washout before a planned pregnancy differs by molecule, at least two months for semaglutide, while current UK labelling uses one month for tirzepatide, so check the prescribing information for the exact product you take. Breastfeeding advice also depends on the formulation, which makes both conversations named items for the prescriber.

The individual-judgement tier. A history of pancreatitis, where restarting is a case-by-case call. Severe gastroparesis or other significant gut disease, since these drugs slow the stomach further. Diabetic retinopathy, because a rapid fall in glucose can transiently worsen eye disease, so eyes join the baseline in diabetes. Gallbladder disease, with rapid weight loss itself a contributor to stones. Significant kidney disease, where a bad week of vomiting can tip function. And one very rare addition now on European labels for semaglutide specifically: NAION, an optic-nerve condition affecting up to 1 in 10,000 users of that molecule, which makes sudden vision change on treatment an urgent review.¹⁶

And who these are simply not for. Cosmetic use below the treatment thresholds. Anyone with an active eating disorder, where appetite suppression is fuel on a fire. If any item on this list is yours, raise it yourself at the consult without waiting to be asked; the grey zones are exactly what the consultation is for. One more thing belongs beside the list without being on it: these medicines are a poor stand-alone purchase. Protein, resistance training and follow-through decide how much of the loss is fat and how well the result holds, so treat them as part of the prescription even though no rule can force them.

Prescriptions and the law Copy link

The GLP-1 medicines on this page, semaglutide and tirzepatide in every brand and form, are prescription-only Schedule H drugs, and orlistat is prescription-labelled too. The rules are short and worth knowing. These medicines must be prescribed and dispensed in accordance with the current Indian regulatory requirements governing the product and the prescriber, which in practice means a genuine consultation and a valid prescription before any pen or tablet changes hands. Note that under Rule 65(11A) of the Drugs and Cosmetics Rules, 1945, the pharmacist cannot supply a different preparation in place of the one written, so brand switches belong to the prescriber, never the counter. Telemedicine prescribing must follow the National Medical Commission’s telemedicine guidelines. Those rules restrict what can be prescribed based on whether the consultation is a first or a follow-up and, for some categories of medicine, on the consultation mode. A legitimate online programme works inside them, with a real doctor making the decision.

The regulator has spent 2026 underlining all of this. In March, the CDSCO moved against GLP-1 promotion campaigns and non-prescription sale, alongside a health-ministry surveillance drive across retail, online and clinic channels; in May, the DCGI’s circular on unauthorised promotion and distribution directed state regulators to police those same channels.^17,18 The enforcement has a consumer-protection core: unprescribed sale is where counterfeit and unlabelled product moves, and a buyer nobody has screened is a buyer nobody is protecting. Falling prices make skipping the doctor tempting. The medicine itself is the argument against it.

How much does medical weight loss cost in India? Copy link

Worth saying plainly: the medicine is one of four line items. The drug runs from about ₹1,290 a month at the generic floor to ₹25,781 at top-dose Mounjaro listings; both ends are listed MRPs, and retail discounts often land below them. Around it sit the consultation, the tests that were actually indicated, and the plan and follow-up that carry you through titration, the plateau and maintenance.

The consultation and lab figures are indicative city ranges, so treat them as orientation and ask any provider for the itemised total; the medicine range is sourced from current listings.⁹¹⁰¹¹ It is worth being precise about what those other three line items buy, because they look optional on a price-comparison page and are anything but. The consult is what keeps an ineligible person from taking a drug that could harm them, and matches the right molecule to the right patient. The tests catch the diabetes, liver disease or thyroid problem that changes the plan, and later prove the treatment is working beneath the skin. The supervised plan is what protects muscle while the fat goes, manages the weeks where side effects peak, and turns the stopping data from a prophecy into a design problem. Skipping them does not remove those needs; it just leaves them unmet while the pen money is spent anyway. A supervised year and an unsupervised year cost less far apart than they look, and only one of them is designed to protect the result, and you, along the way.

Before starting anything: a doctor confirms candidacy, screens the exclusions and orders what testing is actually indicated. During treatment, persistent vomiting, severe abdominal pain, signs of dehydration or any sudden vision change mean contacting your doctor immediately.

This article is educational and does not replace personalised medical advice. Weight-loss medicines are prescription-only in India: do not start, stop or change treatment without a doctor. Prices move; verify the printed MRP at purchase. Report an error on this page.